Rachna T. Shroff - Concepedia

Author

Rachna T. Shroff

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

H. Nikbakht, Inmaculada Ales, Penny, Robert, R. Shroff, R. T. Shroff, R.T. Shroff, Rachna Shroff, Rachna T Shroff, Rachna T. Shroff, Roel G.W. Verhaak

384

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of Arizona University of Arizona Cancer Center Massachusetts General Hospital Memorial Sloan Kettering Cancer Center

About

Rachna T. Shroff is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	46	6.2K
2	Health Sciences	6	6	488
3	Cell Biology	2	2	26
4	Public Health	1	1	15
5	Biostatistics	1	1	15

Rachna T. Shroff

Publications

11.6K

Citations

H-Index

Page 1

	Year	Citations
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre, Cancer Cell Functional GenomicsPancreatic CancerPathologyCancer GenomicsPancreatic Ductal Adenocarcinoma	2017	2K
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, The Lancet Oncology Gastrointestinal OncologyMedicineBiliary CancerPharmacologyPathology	2020	995
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Journal of Clinical Oncology Surgical OncologyPathologyPhase Ii StudyFgfr2 FusionsOncology	2017	700
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Journal of Clinical Oncology	2020	601
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers Rachna T. Shroff, Milind Javle, Lianchun Xiao, JAMA Oncology	2019	460
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications Chaitanya Churi, Rachna T. Shroff, Ying Wang, PLoS ONE	2014	447
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation Andrew X. Zhu, Teresa Macarulla, Milind Javle, JAMA Oncology	2021	436
Biliary cancer: Utility of next‐generation sequencing for clinical management Milind Javle, Tanios Bekaii‐Saab, Apurva Jain, Cancer	2016	393
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis Randa Tao, Sunil Krishnan, Priya Bhosale, Journal of Clinical Oncology	2015	303

Page 1